Kythera seeks Health Canada approval for submental fat reduction drug
The NDS is based on results from two pivotal Phase III trials, REFINE-1 and REFINE-2, which were reported in late 2013. In these trials, the majority of ATX-101
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.
Data Highlights BIOD-531 was associated with superior glucose control compared to Humalog Mix 75/25 throughout the day of observation. BIOD-531 was also associated with superior glucose control compared
The administration of particulate matter, if present in an intravenous drug, poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary embolism. Other
Conducted on 15 healthy volunteers at Linear Clinical Research’s facility in Perth, Australia, the study validated additional pharmacokinetic parameters associated with the safety and elimination profile that remained